請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16442
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陸哲駒(Jer-Junn Luh) | |
dc.contributor.author | Wan-Ting Huang | en |
dc.contributor.author | 黃琬葶 | zh_TW |
dc.date.accessioned | 2021-06-07T18:15:09Z | - |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-03-27 | |
dc.identifier.citation | 1.Mitragotri S. Sonophoresis: a 50-year journey. Drug Discov Today 2004; 9(17):735-6.
2.Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov Today 2004;9:670-6. 3.Bronaugh RL, Maibach H. Percutaneous absorption: mechanisms- methodology-drug delivery. New York: Marcel Dekker; 1989. 4.Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Rodriguez-Cruz IM, Dominguez-Delgado CL. The use of sonophoresis in the administration of drugs throughout the skin. J Pharm Pharmaceut Sci. 2009; 12(1): 88-115. 5.Ilana L, Joseph K. Ultrasound and transdermal drug delivery. Drug Disc Today 2004, 9(15): 670-6. 6.Tyle P, Agrawala P. Drug delivery by phonophoresis. Pharm Res 1989; 6 (5):355-61. 7.Byl N. The use of ultrasound as an enhancer for transcutaneous drug delivery: phonophoresis. Phys Ther 1995; 75 (6): 539. 8.Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269 (5225):850-3. 9.Mitragotri S, Blankschtein D, Langer R. Transdermal drug delivery using low-frequency sonophoresis.Pharm Res 1996; 13(3):411-20. 10.Tachibana K. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res 1992; 9: 952-4. 11.Merino G, Kalia YN, Delgado-Charro MB, Potts RO, Guy RH. Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis. J Control Release 2003; 88: 85-94. 12.Tachibana K, Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J Pharm Pharmacol 1991; 43: 270-1. 13.Griffin JE, Touchstone JC. Effects of ultrasonic frequency on phonophoresis of cortisol into swine tissues. Am J Phys Med 1972; 51: 62-78. 14.Benson HAE, McElnay JC, Harland R. Use of ultrasound to enhance percutaneous absorption of benzydamine. Phys Ther 1989; 69: 113-8. 15.Miyazaki S, Mizuoka H, Oda M, Takada M. External control of drug release and penetration enhancement of the transdermal absorption of indomethacin by ultrasound irradiation. J Pharm Pharmacol 1990; 43: 115-6. 16.Mitragotri S, Blankschtein D, Langer R. An explanation for the variation of the sonophoretic transdermal transport enhancement from drug to drug. J Pharm Sci 1997; 86: 1190-2. 17.Ueda H, Ogihara M, Sugibayashi K, Morimoto Y. Difference in the enhancing effects of ultrasound on the skin permeation of polar and non-polar drugs. Chem Pharm Bull 1996; 44: 1973-6. 18.Hippius M, Smolenski U, Uhlemann C, Schreiber U, Hoffmann A. Investigations of drug release and penetration-enhancing effect of ultrasound on transmembrane transport of fluofenamic acid. Int J Clin Pharmacol Ther1998; 36:107-11. 19.Singer AJ, Homan CS, Church AL, McClain SA. Low-frequency sonophoresis: pathologic and thermal effects in dogs. Acad Emerg Med 1998; 5(1):35-40. 20.Fang J, Fang C, Sung KC, Chen H. Effect of low frequency ultrasound on the in-vitro percutaneous absorption of clobestol 17-propionate. Int J Pharm 1999; 191:33-42. 21.Merino G, Kalia YN, Guy RH. Ultrasound-enhanced transdermal transport. J Pharm Sci 2003; 92: 1125-37. 22.Tezel A, Mitragotri S. Interactions of inertial cavitation bubbles with stratum corneum lipid bilayers during low-frequency sonophoresis. Biophys J 2003; 85(6): 3502-12. 23.Lavon I, Grossman N, Kost J, Kimmel E, Enden G. Bubble growth within the skin by rectified diffusion might play a significant role in sonophoresis. J Control Release 2007; 117: 246-55. 24.Hynynen K. The threshold for thermally significant cavitation in dog’s thigh muscle in vivo. Ultrasound Med Biol 1991; 17:157-69. 25.Barnett SB. Ultrasound. Nonthermal issues: Cavitation- Its nature, detection and measurement. Ultrasound Med Biol 1998; 24 Suppl 1:S11-21. 26.Meaney PM, Cahill MD, ter Haar GR. The intensity dependence of lesion position shift during focused ultrasound surgery. Ultrasound Med Biol 2000; 26: 441-50. 27.Sarheed O, Abdul Rasool BK. Development of an optimised application protocol for sonophoretic transdermal delivery of a model hydrophilic drug. Open Biomed Eng J 2011;5:14-24. 28.Wilmington DE. EMLA cream and EMLA anesthetic disc prescribing information. AstraZeneca Pharmaceuticals LP, 2001. 29.Gangarosa LP Sr. Defining a practical solution for iontophoretic local anesthesia of skin. Methods Find Exp Clin Pharmacol 1981;3:83-94. 30.Bezzant JL, Stephen RL, Petelenz TJ, Jacobsen SC. Painless cauterization of spider veins with the use of iontophoretic local anesthesia.J Am Acad Dermatol 1988;19: 869-75. 31.Zeltzer L, Regalado M, Nichter LS, Barton D, Jennings S, Pitt L. Iontophoresis versus subcutaneous injection: a comparison of two methods of local anesthesia delivery in children. Pain 1991; 44: 73-8. 32.Irsfeld S, Klement W, Lipfert P. Dermal anaesthesia: comparison of EMLA cream with iontophoretic local anaesthesia. Br J Anaesth 1993;71:375-8. 33.Greenbaum SS, Bernstein EF. Comparison of iontophoresis of lidocaine with a eutectic mixture of lidocaine and prilocaine (EMLA) for topically administered local anesthesia. J Dermatol Surg Oncol 1994;20:579-83. 34.Zhang Y, Brown K, Siebenaler K, Determan A, Dohmeier D, Hansen K. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res 2011, Jul 7. [Epub ahead of print] 35.Kim TY, Jung DI, Kim YI, Yang JH, Shin SC. Anesthetic effects of lidocaine hydrochloride gel using low frequency ultrasound of 0.5MHz. J Pharm Pharm Sci 2007; 10(1): 1-8. 36.Katz NP, Shapiro DE, Herrmann TE, Kost J, Custer LM. Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth Analg 2004; 98(2): 371-376. 37.Coleman AJ, Saunders JE. A review of the physical properties and biological effects of the high amplitude acoustic fields used in extracorporeal lithotripsy. Ultrasonics 1993; 31(2):75-89. 38.Ohl CD, Wolfrum B. Detachment and sonoporation of adherent HeLa-cells by shock wave-induced cavitation. Biochim Biophys Acta 2003; 1624(1–3): 131-8. 39.Bolt DM, Burba DJ, Hubert JD, Strain GM, Hosgood GL, Henk WG, et al.Determination of functional and morphologic changes in palmar digital nerves after nonfocused extracorporeal shock wave treatment in horses. Am J Vet Res 2004;65(12): 1714-8. 40.Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits.J Orthop Res 2003; 21(6): 984-9. 41.Wu YH, Liang HW, Chen WS, Lai JS, Luh JJ, Chong FC. Electrophysiological and functional effects of shock waves on the sciatic nerve of rats. Ultrasound Med Biol 2008; 34(10): 1688-96. 42.Fellinger K, Schmidt J. Klinik and therapies des chromischen gelenkreumatismus. Maudrich Vienna Austria 1954; 549-52. 43.Bommannan D, Okuyama H, Stauffer P, Guy RH.Sonophoresis: I. The use of high frequency ultrasound to enhance transdermal drug delivery. Pharm Res 1992;9:559-64. 44.Mitragotri S, Edwards DA, Blankschtein D, Langer R.A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci 1995; 84: 697-706. 45.Johnson ME, Mitragotri S, Patel A, Blankschtein D, Langer R. Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery.J Pharm Sci 1996; 85: 670-9. 46.Cagnie B, Vinck E, Rimbaut S, Vanderstraeten G. Phonophoresis versus topical application of ketoprofen: comparison between tissue and plasma levels. Phys Ther 2003; 83:707-12. 47.Meidan VM, Michniak BB. Emerging technologies in transdermal therapeutics. Am J Ther, 2004; 11: 312-6. 48.Park EJ, Werner J, Smith NB. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm Res 2007; 24: 1396-401. 49.Tezel A, Sens A, Tuscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001; 18: 1694-700. 50.Boucaud A, Garrigue MA, Machet L, Vaillant L, Patat F. Effect of sonication parameters on transdemral delivery of insulin to hairless rats. J Pharm Sci 2002; 91:113-9. 51.Tachibana K, Tachibana S. Use of ultrasound to enhance the local anesthetic effect of topically applied aqueous lidocaine. Anestheiology 1993; 78: 1091-6. 52.Yuan Y and Verma R. Measuring microelasatic properties of stratum corneum.Coll. Surfaces B Biointerfaces 2006; 48: 6-12. 53.Ellias PM. Epidermal barrier function: intercellular lamellar lipid structures, origin,composition and metabolism, J Control Rel 1991; 15:199-208. 54.Benson HAE. Transdermal drug delivery: penetration enhancement techniques.Current drug delivery 2005; 2(1):23-33. 55.Scheuplein RJ, Blank IH, Brauner GJ, MacFarlane DJ. Percutaneous absorption of steroids. J Invest Dermatol 1969; 52: 63-70. 56.Scheuplein RJ, Blank IH. Permeability of the skin. Physiol Rev 1971; 51(4):702-47. 57.Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci 1962; 51: 802-4. 58.Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. J PharmSci 2001; 14: 101-14. 59.Barry BW. Dermatological Formulations: Percutaneous Absorption. In: Swarbick J, editors. Drugs and the Pharmaceutical Sciences. New York and Basel: Marcel Dekker Inc; 1983: 202. 60.Hadgraft J. Skin, the final frontier. Int J Pharm 2001; 224 (1-2): 1-18. 61.Hadgraft J, Guy RH. Feasibility assessment in topical and transdermal delivery: mathematical models and in vitro studies.In: Guy RH, Hadgraft J, editors.Transdermal Drug Delivery. 2nd ed. New York: Marcel Dekker;2003:1-23. 62.Jarrrett A, Editor. In: The physiology and pathology of the skin. 2nd ed. London:Academic Press;1978. 63.Tang H, Wang C, Blankschtein D, Langer R. An investigation of the role of cavitation in low-frequency ultrasound-mediated transdermal drug transport.Pharm Res 2002; 19 (8): 1160-9. 64.Tezel A, Sens A, Mitragotri S. Investigations of the role of cavitation in low-frequency sonophoresis using acoustic spectroscopy. J Pharm Sci 2002; 91 (2):444-53. 65.Ghosh S, Blankschtein D. The role of sodium dodecyl sulfate (SDS) micelles in inducing skin barrier perturbation in the presence of glycerol, Int J Cosmet Sci 2007; 30:73. 66.Suslick KS. Ultrasound- Its chemical, physical and biological effects. New York:VCH Publishers; 1989. 67.Mitragotri S, Kost J. Low-frequency sonophoresis: A review. Adv Drug Deliv Rev 2004; 56: 589-601. 68.Blake JR, Gibson DC. Cavitation bubbles near boundaries. In: Lumley J, Van Dyke M, Reed H, editors. Ann Rev Fluid Mech 1985; 19: 99-123. 69.Fong S, Klaseboer E, Turangan C, Khoo B, Hung K. Numerical analysis of a gas bubble near bio-materials in an ultrasound field. Ultrasound Med Biol 2006; 32 (6):925-42. 70.Polat B, Figueroa P, Blankschtein D, Langer R. Transport pathways and enhancement mechanisms within localized and non-localized transport regions in skin treated with low-frequency sonophoresis and sodium lauryl sulfate. J Pharm Sci 2011; 100(2): 512-29. 71.Kushner J, Blankschtein D, Langer R. Heterogeneity in skin treated with low-frequency ultrasound. J Pharm Sci 2008; 97(10): 4119-28. 72.Mitragotri S, Ray D, Farrell J, Tang H, Yu B, Kost J, et al. Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal transport.J Pharm Sci 2000;89(7):892-900. 73.Tezel A, Sens A, Tuchscherer J, Mitragotri S. Synergistic effect of low-frequency ultrasound and surfactants on skin permeability, J Pharm Sci 2002; 91 (1): 91-100. 74.Paliwal S, Menon G, Mitragotri S. Low-frequency sonophoresis: ultrastructural basis for stratum corneum permeability assessed using quantum dots.J Invest Dermatol 2006; 126 (5): 1095-101. 75.Polat BE, Seto JE, Blankschtein D, Langer R. Application of the aqueous porous pathway model to quantify the effect of sodium lauryl sulfate on ultrasound-induced skin structural perturbation. J Pharm Sci 2011; 100(4):1387-97. 76.Polat BE, Deen WM, Langer R, Blankschtein D. A physical mechanism to explain the delivery of chemical penetration enhancers into skin during transdermal sonophoresis — Insight into the observed synergism. J Control Rel 2011. 77.Pointon A. Piezoelectric devices.IEE Proc A 1982;129 (5):285-307. 78.Leighton T. What is ultrasound? Prog Biophys Mol Biol 2007;93(1–3):3-83. 79.Baker KG, Robertson VJ, Duck FA. A review of therapeutic ultrasound: biophysicaleffects.Phys Ther 2001; 81(7):1351-8. 80.Sturtevant B. Shock wave physics of lithotriptors. In: Smith AD, Badlani GH,Bagley DH, Clayman RV, Jordan GH, Kavoussi LR, Lingeman JE, Preminger GM,Segura JW, editors. Smith’s textbook of endourology.St Louis: Quality Medical Publishing;1996:529-52. 81.Chaussy C, Schmiedt E, Jocham D, Brendel W, Forssmann B, Walther V. First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. J Urol 1982;127 (3): 417-20. 82.Loew M, Jurgowski W, Mau HC, Thomsen M. Treatment of calcifying tendinitis of rotator cuff by extracorporeal shock waves: a preliminary report.J Shoulder Elbow Surg 1995;4(2):101-6. 83.Rompe JD, Hopf C, Kullmer K, Heine J, Burger R, Nafe B. Low-energy shock wave therapy for persistent tennis elbow. Int Orthop 1996a; 20(1): 23-7. 84.Rompe JD, Hopf C, Nafe B, Burger R. Low-energy extracorporeal shock wave therapy for painful heel:a prospective controlled single-blind study. Arch Orthop Trauma Surg 1996b;115(2):75-9. 85.Hallen B, Olsson GL, Uppfeldt A. Pain-free venepuncture. Effect of timing of application of local anaesthetic cream. Anaesthesia 1984;39:969-72. 86.Hallen B, Carlsson P, Uppfeldt A. Clinical study of a lignocaine-prilocaine cream to relieve the pain of venepuncture.Br J Anaesth 1985;57:326-8. 87.Ehrenstrom Reiz GM, Reiz SL. EMLA-a eutectic mixture of local anaesthetics for topical anaesthesia.Acta Anaesthesiol Scand 1982;26:596-8. 88.Maunuksela EL, Korpela R. Double-blind evaluation of a lignocaine-prilocaine cream (EMLA) in children. Effect on the pain associated with venous cannulation.Br J Anaesth 1986; 58: 1242-5. 89.Young SS, Schwartz R, Sheridan MJ. EMLA cream as a topical anesthetic before office phlebotomy in children. South Med J 1996; 89: 1184-7. 90.Singer AJ, Shallat J, Valentine SM, Doyle L, Sayage V, Thode HC Jr. Cutaneous tape stripping to accelerate the anesthetic effects of EMLA cream: a randomized,controlled trial. Acad Emerg Med 1998; 5: 1051-6. 91.Nott MR, Clemson CJ, Peacock JL. Onset time of topical analgesia with EMLA 5%:no reduction with glyceryl trinitrate. Eur J Anaesthesiol 1996; 13: 17-20. 92.Liu DR, Kirohner HL, Petrack EM. Does using heat with eutectic mixture of local anesthetic cream shorten analgesic onset time?: A randomized, placebo-controlled trial. Ann Emerg Med 2003; 42(1): 27-33. 93.Shiau JM, Su HP, Chen HS, Hung KC, Lin SE, Tseng CC. Use of a topical anesthetic cream (EMLA) toreduce pain after hemorrhoidectomy. Reg Anesth Pain Med 2008; 33(1): 30-5. 94.Rosenthal D, Murphy F, Gottschalk R, Baxter M, Lycka B, Nevin K. Using a topical anaesthetic cream to reduce pain during sharp debridement of chronic leg ulcers. J Wound Care 2001;10(1):503-5. 95.Von Heijne M, Bredlov B, Soderhall S, Olsson GL. Propofol or propofol–alfentanil anesthesia for painful procedures in the pediatric oncology ward.Paediatr Anaesth 2004;14(8):670-5. 96.Sarifakioglu N, Terzioglu A, Cigsar B, Aslan G. EMLA and ear surgery: is it possible to achieve full-thickness anesthesia with EMLA? Dermatol Surg 2004; 30(3): 395-8. 97.Brown FF, Robinson ME, Riley JL 3rd, Gremillion HA, McSolay J, Meyers G.Better palpation of pain: reliability and validity of a new pressure pain protocol in TMD. Cranio 2000; 18(1):58-65. 98.Hehn B, Moll F. Phonophoretic permeation of procaine hydrochloride through and MDCK cell monolayer. Pharmazie 1996; 51: 341-5. 99.Lee YF, liu HN.The antinociceptive effect of transdermal EMLA delivery using sonophoresis. Dermatol sinica 2002; 20: 280-5. 100.Evers H, Von Dardel O, Juhlin L, Ohlsen L, Vinnars E. Dermal effects of compositions based on the eutectic mixture of lignocaine and prilocaine (EMLA).Br J Anaesth 1985; 57:997-1005. 101.McCafferty DF,Woolfson AD. New patch delivery system for percutaneous local anesthesia.Br J Anaesth 1993;71:370-4. 102.Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of EMLA cream. Br J Anaesth 1990; 64: 173-7. 103.Arendt-Nielsen L, Bjerring P. Laser-induced pain for evaluation of local analgesia.Anesth Analg 1988; 67: 115-23. 104.Friedman PM, Fogelman JP, Nouri K, Levine VJ, Ashinoff R. Comparative study of the efficacy of four topical anesthetics. Dermatol Surg 1999; 25: 950-4. 105.Holmes HS. Choosing a local anesthetic. Dermatol Clin 1994; 12: 817-23. 106.Bjerring P, Andersen PH, Arendt-Nielsen L. Vascular response of human skin after analgesia with EMLA cream. Br J Anaesth 1989; 63: 655-60. 107.Lawson RA, Smart NG, Gudgeon AC, Morton NS. Evaluation of an amethocaine gel preparation for percutaneous analgesia before venous cannulation in children.Br J Anaesth 1995; 75: 282-5. 108.Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anesthetics update: EMLA and beyond. Dermatol Surg 2001; 27:1019-26. 109.Kuwabara S, Ogawara K, Misawa S. Sensory nerve conduction in demyelinating and axonal guillain-barre syndromes. Eur Neuro 2004; 51: 196-8. 110.Susan J. Garrison, editor. In: Handbook of physical medicine and rehabilitation:the basics. 2nd ed. Baker & Taylor Books; 1994. 111.Cuccurullo S, editor. In: Physical Medicine and Rehabilitation Board Review.NewYork: Demos Medical Publishing; 2004. 112.Erickson, TE. The postnatal development of the caudal integument in the rat.American Journal of Anato, 2005; 47(1): 173-93. 113.Ovaere P, Lippens S, Vandenabeele P, Declercq W. The emerging roles of serine protease cascades in the epidermis. Trends in Biochemical Scien, 2009; 34 (9):453-63. 114.Durst HB, Blatter G, Kuster MS. Osteonecrosis of the humeral head after extracorporeal shock-wave lithotripsy. J Bone Joint Surg Br. 2002; 84 (5):744-6. 115.Liu HM, Chao CM, Hsieh JY, Jiang CC. Humeral head osteonecrosis after extracorporeal shock-wave treatment for rotator cuff tendinopathy. A case report. J Bone Joint Surg Am. 2006; 88 (6): 1353-6. 116.Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release, 2011; 152 (3): 330-48. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16442 | - |
dc.description.abstract | 背景與目的: 傳統上低頻超音波應用於超音波導入法(sonophoresis)已被認為是增進藥物經皮傳輸之有效方式。目前普遍認為超音波導入法中增加皮膚通透性的機轉為空泡效應(cavitation effect)。體外震波(extracorporeal shockwave)相對於其他形式的醫用超音波更能有效地產生短暫的空泡效應且熱效應較低,故使用體外震波應可較超音波在聲波導藥上有更好效果。然而體外震波有可能造成神經受損,使用時震波可能造成人體皮膚不舒服的感覺。因此找出安全有效的震波導藥劑量可減少不適感而使病人有較好的順從度,並提昇導藥的安全性。目前仍無研究探討震波經皮導入麻醉藥物的效果。本研究目的為: (1)利用先驅實驗找到之合適震波參數,經由震波輔助預先導入及同時導入安麻樂(Eutectic Mixture of Local Anaesthetics, EMLA cream)局部麻醉乳膏的動物實驗,同時與超音波導入法、直接塗抹EMLA法比較,探討體外震波經皮導入麻醉藥之效果。(2)用較低強度或較低脈衝數之震波,探討體外震波經皮導入EMLA之劑量反應。
方法: 本研究使用二十四隻平均年齡20.9週之成年雄性 Wistar 大鼠為實驗對象。在震波經皮導藥研究中,大鼠被隨機分配至以下的組別:局部塗藥組、超音波導藥組(1MHz)、震波預先導藥組及震波同時導藥組,於大鼠尾巴進行經皮導入EMLA,每次實驗時間為六十分鐘。過程中以神經傳導研究在每次治療前五分鐘及治療後一小時內每五分鐘測量所得之感覺神經動作電位的振幅和潛伏時間來評估麻醉程度。一週後的劑量反應研究中,大鼠被分配至四個組別,接受較低脈衝數和強度的震波輔助 EMLA局部麻醉藥物導入,來測定此應用的最小劑量。 結果: 震波預先導藥組和震波同時導藥組,比超音波導藥組更能於大鼠尾巴提供較好的經皮導藥效果(p<0.05)。此外,震波同時導藥組的經皮導藥效果又明顯優於震波預先導藥組(p<0.05)。震波同時導藥組在五分鐘內就有明顯的效果,顯著快於震波預先導藥組。而較低強度(0.055 mJ/mm2)和較低脈衝數(500 pulse)的震波,也明顯比EMLA局部塗藥組有好的經皮導藥效果(p<0.05)。 結論:本研究使用之震波導藥安全參數,其導入EMLA的效果比超音波導入法好,不僅有更好的麻醉程度而且顯著縮短了EMLA在健康成年雄性大鼠尾巴神經發揮麻醉效果的時間,而震波同時導入法比震波預先導入法為更好的導藥方式。此外,較低強度(0.055mJ/mm2)或脈衝數(500 pulse)之震波可能為震波導藥所需的最小閾值,其導藥效果雖然略微下降,但是其結果仍然比直接塗抹EMLA為佳。 | zh_TW |
dc.description.abstract | Background and Purpose: Traditionally, low-frequency ultrasound is used for sonophoresis and has been found to be an effective method in enhancing transdermal drug transport. The generally accepted mechanism responsible for skin permeability enhancement by sonophoresis is the cavitation effect. Extracorporeal shockwave can provide more transient cavitation than most other forms of medical ultrasound, with less thermal effect. Thus, it might have better clinical effects than ultrasound in sonophoresis. However, extracorporeal shockwave might induce nerve damage and cause uncomfortable sense on human skin. Therefore to determine the reasonable dosage of shockwave to reduce the uncomfortableness and induce better compliance of patients is crucial for safety consideration. There is no study founded to explore the sonophoretic effect of shockwave on transdermal delivery of anesthetic drug. Therefore, the purposes of this study were (1) to use the determined suitable parameters of shockwave to identify the sonophoretic effect of extracorporeal shockwave by using the pre- or concurrent shockwave-aided EMLA(eutectic mixture of local anesthetics) application, and simultaneously compared with the sonophoresis-aided EMLA application and topical EMLA application via an animal study. (2) to determine the dose-response of the sonophoretic effect of extracorporeal shockwave with lower intensities or pulses.
Methods: Twenty-four Wistar rats with a mean age of 20.9 weeks were used as the experimental subject in this study. In the shockwave sonophoresis study, the rats were assigned to following groups randomly: topical, sonophoresis-aided (1MHz ultrasound), pre- and concurrent shockwave-aided EMLA application on the rat tails for 60 minutes. The degree of anesthesia was assessed using the amplitude and latency of sensory nerve action potential which were evaluated by nerve conduction study (VikingQuest, Nicolet, VIASYS Healthcare, USA) before and every 5 minutes after treatment for 60 min. One week later, in the dose-response study, rats were divided into four groups to received shockwave mediated EMLA delivery with different pulse number and intensity to determine the possible minimal dosage in this application. Results: The pre-treated and concurrent shockwave could provide better effectiveness on transdermal delivery of EMLA cream on the nerve of tail than pre-treated 1 MHz ultrasound (p<0.05). Besides, the concurrent shockwave mediated drug delivery was superior to pre-treated shockwave (p<0.05). After the concurrent shockwave application, the effects of EMLA were evident within 5 minutes, which is much quicker than pre-treatment shockwave application (p<0.05). The concurrent extracorporeal shockwave with lower intensity of 0.055 mJ/mm2 or lower 500 pulse could also show better effectiveness on transdermal delivery of EMLA cream on caudal nerve in healthy male adult rats than topical EMLA application (p<0.05). Conclusions: The safety parameters of 4Hz, 1000 pulses with 0.089mJ/mm2 intensity of extracorporeal shockwave could show better effectiveness on transdermal delivery of EMLA cream than sonophoresis-aided EMLA application, and resulted in better degree of anesthesia and shortening the onset time of anesthetic effect to 5 minutes on caudal nerve in healthy male adult rats. It would be that the concurrent shockwave-aided EMLA application was superior to the pre shockwave-aided EMLA application. Lower intensities (0.055mJ/mm2) or pulses (500 pulse) of extracorporeal shockwave might be the minimal threshold for shockwave sonophoresis and could show better effectiveness on transdermal delivery of EMLA cream than the topical EMLA application. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:15:09Z (GMT). No. of bitstreams: 1 ntu-101-R99428006-1.pdf: 3119019 bytes, checksum: f6958cce8ed489aebd4759f53f9a60b4 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 誌謝...ii
中文摘要...iii Abstract...v Chapter1. Introduction...1 1.1 Background...1 1.2 Purposes and Hypotheses...7 1.2.1 Questions and Hypotheses for the Purposes...7 Chapter2. Literature Review...10 2.1 Sonophoresis...10 2.2 Drug Delivery Routes across Human Skin...12 2.3 Mechanisms of Skin Permeability Enhancement in Sonophoresis...14 2.4 Physical principles...18 2.4.1 Ultrasound...18 2.4.2 Shockwave...18 2.5 The Effects of Shockwave on Peripheral Nerve...19 2.6 EMLA...20 Chapter3. Materials and Methods...25 3.1 Experimental Procedure...25 3.2 Experimental Animals...25 3.3 EMLA...26 3.4 Study Design...27 3.4.1 Pilot Study...27 3.4.2 Shockwave Sonophoresis Study...28 3.4.3 Dose-Response Study...30 3.4.4 Assessment---Sensory Nerve Conduction Studies...30 3.4.5 Morphological Observation...31 3.5 Sample Size Estimated...33 3.6 Statistical Analysis...33 3.7 Further Data Analysis...34 Chapter4. Results...36 4.1 Shockwave Sonophoresis Study...36 4.1.1 Basic data: Basic Demographic and Pre-Intervention Assessments...36 4.1.2 Pre- and Post-60min Application in Different Groups...36 4.1.3 The Trend of Change in Different Groups during 60 Minutes Application...37 4.1.4 Time to Target in Different Groups...38 4.1.5 Relative Change to 60-Min EMLA Application at Time to Target in Different Groups...38 4.2 Dose-Response Study...39 4.2.1 Basic data: Basic Demographic and Pre-Intervention Assessments...39 4.2.2 Pre- and Post-60min Application in Different Groups...39 4.2.3 The Trend of Change in Different Groups during 60 Minutes Application...40 4.2.4 Time to Target in Different Groups...41 4.2.5 Relative Change to 60-Min EMLA Application at Time to Target in Different Groups...41 4.3 Morphological Observation...42 Chapter5. Discussions...43 5.1 Major Findings...43 5.1.1 Shockwave Sonophoresis versus 1 MHz Ultrasound and Topical EMLA Application...43 5.1.2 Lower Intensity and Lower Pulse of Shockwave Sonophoresis...44 5.2 Mechanism for the Immediately Rapid Descending Amplitude in the Concurrent Shockwave Sonophoresis...45 5.3 The Possible Reasons for the Different Change of Amplitude and Latency...46 5.4 Comparison with Previous Studies...47 5.5 Hints for Clinical Implication...48 5.6 Study Limitations and Future Studies...49 5.7 Conclusions...51 References...52 | |
dc.language.iso | en | |
dc.title | 體外震波治療對於大鼠尾部神經經皮導入藥物之效果 | zh_TW |
dc.title | The Effects of Extracorporeal Shockwave Mediated Transdermal Drug Delivery in Rat Caudal Nerves | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林光華(Kwan-Hwa Lin),陳文翔(Wen-Shiang Chen) | |
dc.contributor.oralexamcommittee | 黃義侑(Yi-You Huang),郭柏齡(Po-Ling Kuo) | |
dc.subject.keyword | 聲波導藥,體外震波,空泡效應,麻醉藥物,感覺神經傳導, | zh_TW |
dc.subject.keyword | Sonophoresis,Extracorporeal shockwave,Cavitation effect,Analgesic drug,Sensory nerve conduction, | en |
dc.relation.page | 101 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-03-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 物理治療學研究所 | zh_TW |
顯示於系所單位: | 物理治療學系所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.05 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。